BenzingaSeptember 3, 2026 at 9:32 AM NYLast Month
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
